Pharma companies sell molecules, trial data, and the regulatory packages that turn them into one another. Our 2026 analysis of 199 pharma, biotech, and CRO firms found a structural gap: governance stops at the sponsor's door, and that's no longer governance at all. Benchmark your organization against the industry average of 39.6/40 and find your specific exposure.
The 8-dimensional exposure index used to score 199 pharma, biotech, and CRO organizations
Why a single Phase III trial creates a data supply chain no sponsor can fully see or govern
The shadow AI reality: 38% of sponsors confirm AI tool use, and why that's the floor, not the ceiling
PDF · 12 pages
15 min read
Free download
Fill in your details and we’ll send the download to your inbox immediately.
No spam. Unsubscribe any time. By submitting you agree to our Privacy Policy.
How we scored 199 pharma, biotech, and CRO organizations across an 8-dimensional structural risk model, and where the industry average actually sits.
Why governance disappears the moment a file leaves the platform, and how a single Phase III trial creates a data supply chain no sponsor can fully see.
The shadow AI reality behind the 38% of sponsors running confirmed AI tools, and a worksheet to quantify what unmanaged exposure is actually costing you.